Key findings include (1) marked fiber-type-specific athletic performance gains from pathological androgens, (2) rare BCOR/HDAC9 mutations expanding the molecular spectrum of ACC, and (3) aggressive treatment and long-term management yielding >8-year disease-free survival. The gene discussed is HDAC9; the disease is adrenal cortex carcinoma.